Evidence map›Paper›PMID 31167060›Full record

ArticleThe New England journal of medicine2019

Macrolide Resistance in MORDOR I - A Cluster-Randomized Trial in Niger.

Thuy Doan, Ahmed M Arzika, Armin Hinterwirth, Ramatou Maliki, Lina Zhong, Susie Cummings, Samarpita Sarkar, Cindi Chen, Travis C Porco, Jeremy D Keenan and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04224987 (Azithromycine Pour la Vie Des Enfants au Niger - Implémentation et Recherche), which is not on this map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04224987 phase4completednot on this mapstarted 2020, after this paper: background citation

Azithromycine Pour la Vie Des Enfants au Niger - Implémentation et Recherche: Essai mortalité et résistance (Azithromycin for Child Survival in Niger: Mortality Trial and Resistance Trial)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2020 to 2024Enrolled864,493ConditionsMortality, Resistance Bacterial, Child, OnlyArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Prevalence of nasopharyngealThe Lancet. Microbe · 2022
    Trial

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Thuy DoanFrancis I. Proctor Foundation, San Francisco, CA thuy.doan@ucsf.edu.
Ahmed M ArzikaCarter Center, Niamey, Niger.
Armin HinterwirthFrancis I. Proctor Foundation, San Francisco, CA.
Ramatou MalikiCarter Center, Niamey, Niger.
Lina ZhongFrancis I. Proctor Foundation, San Francisco, CA.
Susie CummingsFrancis I. Proctor Foundation, San Francisco, CA.
Samarpita SarkarFrancis I. Proctor Foundation, San Francisco, CA.
Cindi ChenFrancis I. Proctor Foundation, San Francisco, CA.
Travis C PorcoFrancis I. Proctor Foundation, San Francisco, CA.
Jeremy D KeenanFrancis I. Proctor Foundation, San Francisco, CA.
Thomas M LietmanFrancis I. Proctor Foundation, San Francisco, CA.
MORDOR Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Administration, OralAnti-Bacterial AgentsAzithromycinChild, PreschoolDrug Resistance, BacterialHumansInfantMacrolidesNigerPneumococcal InfectionsStreptococcus pneumoniaeAnti-Bacterial AgentsAzithromycinMacrolides

Identifiers

PMID31167060
PMCPMC6518950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.